.png)
See If You Qualify for Compensation
Take just a few minutes to complete our confidential intake form. It’s fast, secure, and could be the first step toward the justice and compensation you deserve.
100% Free Case Review
No Fee Unless We Win
Help is One Step Away
Don’t wait — your health and future matter. Fill out the form now to see if you qualify.
Ozempic and Vision Loss (non-arteritic anterior ischemic optic neuropathy (NAION))
There have been additional lawsuits against Novo Nordisk and Eli Lilly that allege that the pharmaceutical companies failed to adequately warn of the risk of vision loss or optic neuropathy. Some research found that patients who have taken these drugs have a higher risk of this condition referred to as NAION. The condition occurs due to loss of blood flow to the front of the optic nerve, leading to vision loss in one or both eyes that may be permanent.
Current warning labels list changes in vision as a potential side effect, they do not mention the potential for optic neuropathy. Lawsuits assert that they do not go far enough to warn about the risk of unreasonably dangerous consequences, such as NAION.
A diagnosis of NAION after using semaglutide, tirzepatide, liraglutide, or other GLP-1 receptor agonists, may entitle you to bring a lawsuit.
These drugs were advertised and sold under the following trade names:
-
Ozempic
-
Wegovy
-
Rybelsus
-
Mounjaro
-
Victoza
-
Saxenda